Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist engineered for superior obesity treatment, achieving 15-20% weight loss over 46 weeks through synergistic appetite suppression (GLP-1) and energy expenditure increase (glucagon), outperforming semaglutide in preclinical models with significant waist circumference and BMI reductions at doses >2mg weekly. Phase 2 trials confirm dose-dependent efficacy, with higher doses (>4.5mg) yielding maximal fat loss while preserving lean mass.
Route
Subcutaneous injection
Dose range
1.2 mg – 4.8 mg
Frequency
Cycle length
Overview
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist engineered for superior obesity treatment, achieving 15-20% weight loss over 46 weeks through synergistic appetite suppression (GLP-1) and energy expenditure increase (glucagon), outperforming semaglutide in preclinical models with significant waist circumference and BMI reductions at doses >2mg weekly. Phase 2 trials confirm dose-dependent efficacy, with higher doses (>4.5mg) yielding maximal fat loss while preserving lean mass.
The glucagon component accelerates hepatic fat clearance and brown adipose activation, addressing metabolic syndrome components beyond pure caloric restriction. Gastrointestinal tolerability improves with titration. For obesity with comorbidities (fatty liver, dyslipidemia), survodutide positions as advanced dual-agonist therapy bridging GLP-1 monotherapy limitations.
Studied benefits
- A dual-action agonist that provides significant, dose-dependent weight loss (up to 15% over 46 weeks)
- It also shows promise for improving liver health biomarkers in patients with fatty liver diseases (NAFLD/NASH)
Reported side effects
- Side effects are primarily gastrointestinal, including nausea, vomiting, and diarrhea, particularly during the dose-escalation phase
- Gradual titration is recommended to manage these effects
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Survodutide (10mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 5 mg/mL).
Support metabolic improvement and weight management through dual GLP-1/glucagon receptor activation.
| Week | Weekly Dose (mg) | Draw at 5 mg/mL | Log |
|---|---|---|---|
| Units (mL) | Weeks 1–2 | 0.6 mg | + Log |
| 600 mcg | 12 units (0.12 mL) | Weeks 3–4 | + Log |
| 1.2 mg | 1200 mcg | 24 units (0.24 mL) | + Log |
| Weeks 5–6 | 1.8 mg | 36 units (0.36 mL) | + Log |
| 36 units (0.36 mL) | Weeks 7–8 | 2.4 mg | + Log |
| 2400 mcg | 48 units (0.48 mL) | Weeks 9–10 | + Log |
| 3.6 mg | 3600 mcg | 72 units (0.72 mL) | + Log |
| Weeks 11–12 | 4.8 mg | 96 units (0.96 mL) | + Log |
| 96 units (0.96 mL) | Week 13+ | 6.0 mg | + Log |
- 6000 mcg
- 120 units (1.20 mL)*
- - Frequency: Once per week (subcutaneous).
- - Timing: Same day each week; rotate injection sites.
- - Cycle Length: 12–16 weeks.
Unit calculator
Set your vial and water; the table above updates.
5 mg/mL
8 doses of 1.2 mg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to safeguard lean muscle mass while this dual GLP-1 and Glucagon receptor agonist works to suppress appetite and increase energy expenditure through thermogenesis. Incorporate regular physical activity, including resistance training, to maximize the peptide's unique metabolic profile and improve cardiovascular health. Ensure 7–9 hours of quality sleep to regulate hunger hormones and support metabolic restoration. Maintain optimal hydration and consume smaller, frequent meals to manage potential gastrointestinal side effects associated with delayed gastric emptying.
Evidence
Research summaries
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Findings: Helps people lose a lot of body weight, up to 12% in about 11 months, especially for those who are overweight without diabetes. It's safe like other similar medicines, with mostly tummy issues that go away.
Imagine being overweight and trying to lose pounds—it's tough! This study tested survodutide on 283 adults who had a BMI over 27 but no diabetes. They got shots once a week for 46 weeks, with doses going up to 4.8 mg. The highest dose group lost an average of 14.9 kg (about 33 pounds), which is 12% of their starting weight, compared to just 2% on fake medicine (placebo). Over half the people on the top dose lost 15% or more of their weight—that's like dropping from 200 pounds to 170! Side effects were mostly nausea, vomiting, and diarrhea, like with other weight-loss shots, but they got better over time. No serious heart or liver problems popped up more than with placebo. This shows survodutide could be a game-changer for obesity, working better than some single-hormone drugs by teaming up two body signals: one that makes you feel full (GLP-1) and one that burns fat (glucagon).
Read the study ↗Once-weekly survodutide (BI 456906) versus placebo and semaglutide 1.0 mg in subjects with type 2 diabetes mellitus: a 46-week, multicentre, phase II randomised trial
Findings: Lowers blood sugar (HbA1c) by 1.5-1.7% and cuts body weight by up to 8.7% in people with type 2 diabetes, better than some common treatments.
Type 2 diabetes means your body struggles with sugar in the blood, and extra weight makes it worse. Researchers gave survodutide to 158 people with diabetes for 16 weeks (extendable to 46). At 4.8 mg weekly, it dropped their HbA1c (a sugar average over months) by about 1.4%, similar to semaglutide (a popular drug like Ozempic) but with more weight loss—up to 8.7% off body weight versus 5.3% for semaglutide. That's like losing 17 pounds if you start at 200! It worked by mimicking two gut hormones: GLP-1 to curb appetite and glucagon to boost energy use. Tummy side effects happened in 78% but were mild and dropped with slower dose increases. This trial proves survodutide tackles both sugar control and weight in one shot, helping diabetics feel better and healthier without big risks.
Read the study ↗Perspectives in weight control in diabetes - Survodutide
Findings: Great for diabetes patients needing to control blood sugar and shed pounds at the same time, with strong results in real trials.
Diabetes often comes with weight gain, making it a double problem. This review looks at survodutide's phase 2 trial data, showing it cuts HbA1c by 1.5-1.7% and weight by 12% in obese diabetics. It's like a superhero hormone combo from your gut—GLP-1 slows digestion so you eat less, and glucagon tells your liver to burn fat instead of storing it. Compared to just GLP-1 drugs, adding glucagon amps up the weight loss without messing up blood sugar. Safety was good; no more serious issues than placebo. For kids your age learning health, think of it as tuning your body's "full" signal and fat-burner to fight obesity and diabetes together. Phase 3 trials are coming to confirm for everyday use.
Read the study ↗Evaluating the efficacy and safety of survodutide for obesity
Findings: Safe weight loss option that matches top drugs, reducing liver fat and improving obesity signs.
Obesity hurts your liver too, building up fat there. This paper reviewed survodutide trials, finding it slashed weight by 12-15% and tackled fatty liver in overweight folks. In one study, it outperformed placebo big time, with folks losing sustainable weight over months. Side effects? Mostly gut stuff early on, but kidneys and heart stayed fine. It's promising because it hits two receptors for double power: feeling full longer and using energy smarter. For a 9th grader, picture your body as a car—survodutide cleans the fuel tank (liver) and makes the engine efficient (weight loss). Doctors are excited for bigger tests.
Read the study ↗Identification
Chemistry
- cas
- Not yet assigned (investigational drug designation)
- formula
- Estimated C₁₆₆H₂₅₁N₄₃O₅₁S (core 29-amino acid peptide; variations based on modifications and counter-ions)
- molecular weight
- Approximately 3,750-3,800 Da (core peptide); approximately 4,000-4,100 Da with C18 fatty acid conjugate and associated modifications
- source
- Synthetic; recombinant DNA-derived; engineered glucagon analog incorporating GLP-1 residues
- biosynthesis
- Recombinant protein production (bacterial expression systems); post-synthetic chemical modifications
- type
- Linear 29-amino acid peptide with post-translational modifications
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks